CL1-068587-002-laysummary-2021.09.08

Home » Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). – CALM study » CL1-068587-002-laysummary-2021.09.08

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.

Accessibility